María José Buzón Gómez I am a researcher with extensive training in virology and immunology and a strong interest in translational research. I am dedicated to the study of new therapies aimed at curing HIV, with special emphasis on the characterization, both in blood and in different tissues, of new cellular reservoirs of HIV and the development of strategies that enhance the immune system. Recently part of my research has been directed to the study of SARS-CoV-2. Institutions of which they are part Head of group Infectious Diseases Vall Hebron Institut de Recerca LinkedIn Twitter Orcid Email María José Buzón Gómez LinkedIn Twitter Orcid Email Institutions of which they are part Head of group Infectious Diseases Vall Hebron Institut de Recerca I am a researcher with extensive training in virology and immunology and a strong interest in translational research. I am dedicated to the study of new therapies aimed at curing HIV, with special emphasis on the characterization, both in blood and in different tissues, of new cellular reservoirs of HIV and the development of strategies that enhance the immune system. Recently part of my research has been directed to the study of SARS-CoV-2.
Since 2015, I am the head of the HIV Translational Research Laboratory, located at the Vall d'Hebron Research Institute (VHIR), which belongs to the Infectious Diseases Department. I obtained my PhD in 2010 at AIDS Research Institute, Irsicaixa in Barcelona, and completed my postdoctoral training at the Ragon Institute of MGH, MIT and Harvard in Boston, where I was promoted to Instructor in Medicine at Harvard Medical School in 2014. My scientific interest has focused on the study of the HIV reservoirs that persist despite antiretroviral therapy (ART). I provided the first evidence that new rounds of cryptic viral replication were happening in the presence of ART (Nat Med 2010), and identified reservoir cells with stem-cell-like properties contributing to HIV long-term persistence (Nat Med 2014). My investigations are now focused on the characterization of new cellular reservoirs, the identification of novel latency reversal agents, and the design of new immune-targeted approximations aimed at depleting the latent reservoir. Recently, my lab has identified the new marker CD20 as a potential target for the transcriptionally active HIV reservoir (Nat Com 2019), has characterized the fraction of virus that can be awakened with current latency reversal agents in different populations (Plos Path 2019), and has developed new nanotechnological strategies for the elimination of the viral reservoir (NanoToday 2021). Besides, I am also a member of several evaluation panels (MINECO and AES grant calls), act as an abstract reviewer for several congresses (CROI, IAS and GESIDA), and participate in different scientific committees and international collaborative networks (BEAT-HIV Delaney Collaboratory Group). I have also contributed to innovation with 3 research patents. Importantly, I have been a recipient of several awards, including the CFAR Young Investigator Award (Harvard University Center for AIDS Research), the MGH ECOR Tosteson Award and the “International Raising Talents 2016” from the L'Oreal-Unesco Foundation For Women in Science. A complete list of publications can be found here https://www.ncbi.nlm.nih.gov/myncbi/1TwfYvrCsLtkW/bibliography/public/
Projects Desenvolupament de noves nanopartícules funcionals dirigides al nòdul limfàtic per a l'eliminació del reservori latent de VIH IP: María José Buzón Gómez Collaborators: Ibane Abasolo Olaortua, Félix Pumarola Segura, Juan Lorente Guerrero, Laura García Latorre, Jordi Temprana Salvador, Joaquin Seras Franzoso, Marc Pellicer Sarasa, David Perea Pérez, Simon Schwartz Navarro, Jordi Navarro Mercadé, Sandra Mancilla Zamora, Zamira Vanessa Diaz Riascos, Judit Grau Exposito, Meritxell Genesca Ferrer, Fernanda Raquel Da Silva Andrade, Diana Fernandes de Rafael Funding agency: Fundació La Marató de TV3 Funding: 199998.75 Reference: 20180510 Duration: 10/05/2019 - 31/12/2022 Nuevas estrategias terapéuticas dirigidas a las células Natural Killers para la eliminación del reservorio latente del VIH (NKcuraVIH) IP: María José Buzón Gómez Collaborators: Estrella Caballero Requero Funding agency: Ministerio Economía, Industria y Competitividad Funding: 217800 Reference: RTI2018-101082-B-I00 Duration: 01/01/2019 - 30/06/2022 Targeting Myeloid-Derived Suppressor Cells to prevent HIV/STI acquisition IP: Meritxell Genesca Ferrer Collaborators: Maria Cristina Centeno Mediavilla, Nuria Laia Rodriguez Mias, Yannick Hoyos Mallecot, Josep Castellví Vives, Laura Mañalich Barrachina, María José Buzón Gómez, Maider Arando Lasagabaster, Bibiana Planas Ribas, Cristina Mancebo Perez Funding agency: Fundació La Marató de TV3 Funding: 199685 Reference: 20181410 Duration: 10/05/2019 - 31/12/2022 . Targeting residual inflammation for the elimination of specific cellular HIV reservoirs in ART-treated individuals IP: María José Buzón Gómez Collaborators: - Funding agency: GILEAD SCIENCES SLU Funding: 49997.2 Reference: GLD17/00204 Duration: 16/01/2018 - 15/01/2020 Pagination First page « Previous page ‹ … Page 4 Page 5 Current page 6 Page 7 Page 8 … Next page › Last page »
